GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (TSXV:RX) » Definitions » Cyclically Adjusted Revenue per Share

Biosyent (TSXV:RX) Cyclically Adjusted Revenue per Share : C$1.92 (As of Mar. 2024)


View and export this data going back to 1979. Start your Free Trial

What is Biosyent Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Biosyent's adjusted revenue per share for the three months ended in Mar. 2024 was C$0.652. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is C$1.92 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Biosyent's average Cyclically Adjusted Revenue Growth Rate was 15.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 19.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 19.60% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 25.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Biosyent was 40.40% per year. The lowest was 3.60% per year. And the median was 24.70% per year.

As of today (2024-06-07), Biosyent's current stock price is C$9.18. Biosyent's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was C$1.92. Biosyent's Cyclically Adjusted PS Ratio of today is 4.78.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biosyent was 57.95. The lowest was 3.77. And the median was 10.62.


Biosyent Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Biosyent's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosyent Cyclically Adjusted Revenue per Share Chart

Biosyent Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.93 1.09 1.34 1.61 1.86

Biosyent Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.67 1.74 1.81 1.86 1.92

Competitive Comparison of Biosyent's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Biosyent's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biosyent's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biosyent's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Biosyent's Cyclically Adjusted PS Ratio falls into.



Biosyent Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biosyent's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.652/126.2576*126.2576
=0.652

Current CPI (Mar. 2024) = 126.2576.

Biosyent Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.212 99.473 0.269
201409 0.251 99.394 0.319
201412 0.218 98.367 0.280
201503 0.228 99.789 0.288
201506 0.248 100.500 0.312
201509 0.321 100.421 0.404
201512 0.267 99.947 0.337
201603 0.260 101.054 0.325
201606 0.301 102.002 0.373
201609 0.328 101.765 0.407
201612 0.328 101.449 0.408
201703 0.263 102.634 0.324
201706 0.388 103.029 0.475
201709 0.372 103.345 0.454
201712 0.398 103.345 0.486
201803 0.306 105.004 0.368
201806 0.406 105.557 0.486
201809 0.361 105.636 0.431
201812 0.407 105.399 0.488
201903 0.311 106.979 0.367
201906 0.367 107.690 0.430
201909 0.451 107.611 0.529
201912 0.410 107.769 0.480
202003 0.447 107.927 0.523
202006 0.365 108.401 0.425
202009 0.446 108.164 0.521
202012 0.446 108.559 0.519
202103 0.574 110.298 0.657
202106 0.565 111.720 0.639
202109 0.521 112.905 0.583
202112 0.566 113.774 0.628
202203 0.555 117.646 0.596
202206 0.524 120.806 0.548
202209 0.544 120.648 0.569
202212 0.604 120.964 0.630
202303 0.525 122.702 0.540
202306 0.649 124.203 0.660
202309 0.736 125.230 0.742
202312 0.689 125.072 0.696
202403 0.652 126.258 0.652

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Biosyent  (TSXV:RX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Biosyent's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=9.18/1.92
=4.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biosyent was 57.95. The lowest was 3.77. And the median was 10.62.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Biosyent Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Biosyent's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Biosyent (TSXV:RX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (TSXV:RX) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
Address
2476 Argentia Road, Suite 402, Toronto, Mississauga, ON, CAN, L5N 6M1
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.
Executives
Peter Douglas Lockhard Director

Biosyent (TSXV:RX) Headlines

No Headlines